Our observation that FBXO11 levels are reduced in secondary and tAML specimens provides a rationale for further in vivo modeling of FBXO11 loss in AML models and in the development of strategies to overcome its deficiency. This evidence concerns the gene FBXO11 and acute myeloid leukemia.